Background Diabetic kidney disease (DKD) is a chronic complication of diabetes mellitus (DM). DKD and chronic kidney disease (CKD) are both long-term conditions requiring ongoing patient care. Individuals living with DKD or CKD can benefit from mobile apps that support effective self-management. However, limited evidence is available about what mobile apps features are commonly included for DKD.

Objective This scoping review aimed to identify the features of mobile applications on self-management for individuals with DKD, DM or CKD.

Methods The review followed the Joanna Briggs Institute (JBI) methodology for scoping reviews and adhered to PRISMA-ScR reporting guidelines. Five databases (PubMed, Scopus, SAGE Journals, ScienceDirect, and Web of Science) were searched from inception to February 26, 2025. Studies were included if they reported on mobile apps supporting self-management in adults with DKD, DM or CKD. DM and CKD apps were included due to similar self-management needs such as blood sugar or blood pressure tracking that are also relevant to people with DKD. Data were extracted on study characteristics, app features, use of technology, integration with care teams, and reported outcomes.

Results Out of 3521 records identified, eleven studies met the inclusion criteria. Five studies focused on CKD, two on DKD, and four on diabetes. Across the eleven mobile apps reviewed, four core domains of self-management were identified: self-care monitoring (91%), educational components (64%), patient support and motivation (100%), and performance incentives (18%). Four apps employed wearable devices and incorporated supportive devices such as Bluetooth glucometers. However, only two apps included real-time communication features with providers integration with healthcare teams and gamification strategies.

Conclusions Mobile apps targeting DKD frequently incorporate monitoring, education, and motivational features. However, consistent integration with healthcare providers and incentive-based engagement strategies remains limited. Future app development should emphasise personalised feedback, clinical integration, and sustained engagement mechanisms to enhance usability and impact.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study did not involve human participants or identifiable personal data. Therefore, ethics approval was not required in accordance with the [name of institution] research ethics guidelines.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

All relevant data are within the manuscript and its Supporting Information files.